Compare IINN & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IINN | CCEL |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 32.7M |
| IPO Year | N/A | 2022 |
| Metric | IINN | CCEL |
|---|---|---|
| Price | $0.56 | $2.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 144.0K | 7.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9,715.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.40 | $3.10 |
| 52 Week High | $1.65 | $6.79 |
| Indicator | IINN | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 18.18 |
| Support Level | $0.55 | N/A |
| Resistance Level | $0.64 | $3.57 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 6.00 | 1.89 |
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.